

## EXAMPLE LETTER OF MEDICAL NECESSITY FOR Avise MCV<sup>SM</sup>

The following is an example letter based on a fictitious patient, physician and insurance entity. Please draft your letter based on the patient's medical history and treatment experience

---

January 1, 2020

Dr. Don Director,  
Medical Director  
1234 Healthplan Way  
Any City, ST 99999

Dear Dr. Director,

I am writing to request full coverage for the Avise MCV<sup>SM</sup> laboratory test for my patient, Susan Sample. I am a board certified rheumatologist practicing at St. John's in San Diego, CA. I consider this test a medically necessary step in the treatment of my patient.

### PATIENT INFORMATION

Patient: Susan Sample  
ID: 0000000011  
Provider: Example Physician, MD  
Date of Service: February 29, 2009

This test aids in determining whether my patient has rheumatoid arthritis and, if so, how aggressively I may need to follow and treat it. *[Note: Please be sure to include all relevant symptoms, treatments, and medical history as it pertains to the patient.]*

### TEST DESCRIPTION

The Avise MCV test measures autoantibodies against mutated citrullinated vimentin. The test can assist in accurately diagnosing rheumatoid arthritis (RA). Elevated levels of mutated citrullinated vimentin ( $\geq 20$  U/ml) are associated with a diagnosis of RA and also provide prognostic information regarding the likelihood of more severe or rapidly progressive forms of RA.

### NETWORK PROVIDER SERVICES

I have chosen the Avise MCV test because of its diagnostic and prognostic capabilities; however, Avise MCV is not available through other network providers as it is a proprietary test only performed by Cypress Bioscience, Inc. at their CLIA certified, CAP accredited San Diego laboratory.

## LABORATORY INFORMATION

For additional information about the Avise MCV test, you may contact Cypress Bioscience directly at 1.888.452.1522, or visit their website at [avisetest.com](http://avisetest.com).

## REFERENCE MATERIALS

- Bang H, Egerer K, et al. Mutation and Citrullination Modifies Vimentin to a Novel Autoantigen for Rheumatoid Arthritis. *Arthritis Rheum.* 2007; 56(8):2503-11.
- Soós L, Szekanecz Z, Szabó Z, et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. *J Rheumatol.* 2007; 34(8):1658-1663.
- Mathsson L, Mullazehi M, et al. Antibodies Against Citrullinated Vimentin in Rheumatoid Arthritis: Higher Sensitivity and Extended Prognostic Value Concerning Future Radiographic Progression as Compared With Antibodies Against Cyclic Citrullinated Peptides. *Arthritis Rheum.* 2008; 58(1):36-45.
- Innala L, Kokkonen H, et al. Antibodies Against Mutated Citrullinated Vimentin Are a Better Predictor of Disease Activity at 24 Months in Early Rheumatoid Arthritis Than Antibodies Against Cyclic Citrullinated Peptides. *J Rheumatol.* 2008; 35(6):1002-8.
- Ursum J, Nielen M, et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. *Arthritis Res Ther.* 2008; 10(1):R12.

Please approve full coverage for Avise MCV.

Thank you for your prompt attention. I look forward to receiving a written response from you within two weeks.

Sincerely,

---

Example Physician, MD  
St. John's Hospital  
22222 North St.  
San Diego, CA 99999  
(123) 456-789